Patent · US Active

Use of agmatine for protection of retinal ganglion cells

US8084502B2 · kind B2 · utility

0Cited by

3References

10Claims

0Family size

Inventors

Gong Je Seong · Seoul, KR
Chan KIM · Seoul, KR
Jong Eun Lee · Seoul, KR
Samin Hong · Seoul, KR

Key dates

Filing date	Apr 3, 2008
Grant date	Dec 27, 2011
Priority date	—
Expiry date	Apr 3, 2028

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P9/10
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A use method of agmatine or a pharmaceutically allowable salt thereof, and a pharmaceutical composition comprising the same are disclosed. The method and pharmaceutical composition of the present invention can effectively cure or prevent eye diseases preferably including glaucoma, retinopathy, and optic neuropathy associated with apoptosis in retinal ganglion cells (RGCs), particularly hypoxia-induced or tumor necrosis factor-α (TNF-α)-induced apoptosis.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.